CIK 0001841387 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Candel Therapeutics, Inc.
Sign in to watch- Ticker
- CADL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 522214851
- Phone
- 617-916-5445
- Business address
- 117 KENDRICK STREET, SUITE 450, NEEDHAM, MA, 02494
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 4 Open-market sale Chief Scientific Officer sold 13,534 shares at $7.23 ($97,783)
- 4 Open-market sale Chief Technology Officer sold 14,322 shares at $7.23 ($103,476)
- 4 Open-market sale See Remarks sold 9,511 shares at $7.23 ($68,717)
- 4 Open-market sale Chief Executive Officer sold 21,704 shares at $7.23 ($156,811)
- 4 Open-market sale Chief Medical Officer sold 10,428 shares at $7.23 ($75,342)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 8-K Event Results of operations · Regulation FD disclosure · Other events
- 4 Open-market sale Chief Scientific Officer sold 13,673 shares at $8.22 ($112,367)
- 4 Open-market sale See Remarks sold 9,971 shares at $8.22 ($81,944)
- 4 Open-market sale Chief Executive Officer sold 21,172 shares at $8.22 ($173,996)
- 4 Open-market sale Chief Technology Officer sold 14,545 shares at $8.22 ($119,534)
- 4 Open-market sale Chief Medical Officer sold 10,799 shares at $8.22 ($88,749)
- 144 Insider Sale of Securities
Page 8 of 22 · 422 filings